PHARMA BRAND PLANNING IN 2024: CONSIDER THESE 3 FACTORS

Every year, pharma marketing teams engage in multi-phased, cross-functional, multi-organizational strategic planning and also in aligning work-stream dubbed “Brand Planning” by many in the industry. Brand planning is often a three-phased process that includes Strategic Planning, Tactical Planning, and Budget Planning. Every quarter, marketing teams (Consumer, HCP, and Payer) align on the brand’s mission, strategic imperatives, and high-level programs. Following that, the marketing team engages both internal and external teams in a tactical ideation process that determines the vast bulk of what the brand will say and do over the next year. Senior marketing leaders typically approve tactical strategies and set budgets for each team at the beginning of the year. While this is usually a well-established and well-understood process, the events over the last 20 months have been anything but typical. Pharma target consumers were forced to use platforms and channels that had been neglected for a long time, with many of those experiences being pleasant. Those positive experiences, as well as the likelihood that those actions will become the new norm, plainly indicate that pharma marketers do not have the luxury of reverting to the typical go-to playbook of “block-and-tackle” techniques that dominated earlier tactical strategies. The traditional approach did not and will not function as well as it formerly did, as evidenced by the data. From a general perspective, despite large gains in site traffic (+16%), pharma website engagement rates were down. The satisfaction of HCPs with their digital encounters has also decreased. Traditional marketing channels have been drastically disrupted by pandemics and social/political/economic crises, which should have prompted pharma marketing teams to shift to more digital approaches, as seen in other industries. The Digital IQ Index: Pharma Rx 2021, on the other hand, clearly demonstrated that while certain companies performed this, quick read-and-react was not universal. Different marketing teams within a single brand were not always in sync. Brand teams that understand the changing nature of marketing and their target audiences have an advantage over their slower-moving competitors, and a growing lead if they have already made changes. Pharma marketing leaders who seek a strategy to catch up or extend their lead should look to the brand planning process as the quickest method to do so. A vast number of pharmaceutical companies use a calendar fiscal year, and the majority of them are presently preparing tactical plans for the calendar year 2024. Prior to committing to those activities, pharma marketing executives should make certain that their teams:

Creative Leave Behind Literatures (LBLs) That 9 X Doctor Engagement

Leave Behind Literatures (LBLs) serves as a powerful tool that allows pharmaceutical marketers to provide tangible resources for doctors to refer to. Here are 9 innovative LBL ideas that enhance engagement with healthcare professionals. By embracing these highly specialized and innovative approaches, pharmaceutical companies can not only engage physicians on a deeper level but also demonstrate their commitment to advancing patient care through the integration of cutting-edge technology and personalized medicine. At eMediWrite, we’re incredibly passionate about creating stunning and engaging LBLs which can help pharma marketers stand out from the competition. If you’d like to know more about how we can help you market your pharma products, drop us a line, we’d love to talk about your projects.

Payment delays for pharma MSMEs are a significant problem

Background Small and medium-sized businesses (SMEs) are the backbone of India’s economy, creating a large amount of jobs and spurring economic expansion. Delay in payments is one of the main issues MSMEs in India deal with, though. Delayed payments put SMEs at a disadvantage compared to large size counterparts, inhibiting their ability to compete effectively in the market, and addressing the issue requires a multi-faceted approach involving various stakeholders. The financial security and long-term viability of these firms are both impacted by the wide-ranging effects of this problem. Causes of late payments to pharmaceutical MSMEs Large enterprises’ ineffective cash flow management, such as slow receivables processing and protracted payment cycles, can negatively affect SMEs by delaying their critical payments. Compared to larger enterprises, pharmaceutical MSMEs typically operate in a weaker bargaining position. Buyers can take advantage of this power disparity by delaying payments without suffering severe consequences. Pharma MSMEs might not have the negotiation leverage or other options necessary to properly handle late payments. Due to administrative inefficiencies, bureaucracy, the ongoing push for improved margins, or a lack of awareness regarding the impact of delayed payments on pharma MSMEs, many purchasers, both private and public bodies, are compelled to employ delayed payment practices. Challenges posed by payments that are late for pharma MSMEs For pharma MSMEs, late payments present formidable obstacles. It interferes with SMEs’ cash flow, making it difficult for them to pay personnel, cover operational costs, and engage in growth projects. Some pharmaceutical MSMEs may even be forced to the verge of closure by this financial pressure. Pharma MSMEs may use pricey alternative financing alternatives as a last resort to close the gap left by delayed payments. This has a detrimental influence on their financial health further by increasing interest costs and debt loads. Delays in payments limit the industry’s capacity to expand operations, make investments in new technologies, or explore new markets due to limited working cash. This limits their ability to grow and stifles the creation of jobs. SMEs are also at a disadvantage when compared to their larger counterparts due to delayed payments, which limits their capacity for effective market competition. Taking care of the situation Payment delays to pharma micro, small, and medium-sized companies (MSMEs) call for a multifaceted strategy including numerous stakeholders. The solution to the issue of delayed payments is collaboration. It is important to encourage pharma MSMEs to join trade organizations so that they can have a stronger collective bargaining position and a unified voice when negotiating improved payment conditions with clients. These 6 tactics can be put into practice to improve the climate for MSMEs and address the problem of late payments to pharma MSMEs in India.

Understand the pivotal role that medical journals play for physicians: The ideal method of pharma-doctor engagement

Medical publications are often highly valued by doctors because they are essential to their professional practice and continuous education. The main source of new and up-to-date information on medical research, clinical trials, treatment recommendations, and developments in medical science is medical journals. Medical publications are valued by doctors for the following 10 reasons: Despite the high value of medical journals, it’s crucial to remember that not all publications are created equally. Doctors frequently place a higher priority on journals with strict peer-review procedures and recognized editorial boards since these elements help to ensure the accuracy and legitimacy of the information presented. In general, medical journals are an essential component of a doctor’s professional arsenal, assisting them in staying informed, making decisions based on the best available information, and giving their patients the best treatment possible.

International Product Management: Navigating the complexities of international markets, including regulatory variations, pricing dynamics, cultural differences, and market access challenges

Globally, market access has drawn a lot of attention as nations struggle to control their rising healthcare costs amid the international economic downturn. Governments have responded by implementing more stringent guidelines for the approval of new products. As a result, pharmaceutical firms are having a harder time addressing the unique issues brought up by diverse governmental, regulatory, and stakeholder entities. The demand for market access services is growing, particularly in developing nations where the complicated and changing healthcare system makes it difficult to get products approved and used. Additionally, emerging markets are currently the primary drivers of growth, making success in these areas crucial for the bulk of pharmaceutical businesses. Due to greater awareness among regulatory and reimbursement authorities of the requirement for value above existing therapies, the market access role has progressively grown in relevance in developed economies. Pharmaceutical businesses have started to integrate the market access function within the organisation in order to deal with this shifting regulatory environment. Only a small number of businesses, however, now have a market access team with well-defined roles and duties. As a result, the majority of pharmaceutical firms today have a fragmented strategy, with sales, marketing, and regulatory departments each handling a portion of the market access duties. A pharmaceutical business will need a complete market access strategy to thrive in such complicated areas. This has to be tailored to meet local difficulties and tightly connected with other business operations. In contrast to established countries, the healthcare environment in developing nations is complicated and lacks a formalised medication approval procedure. For interacting with a wide range of stakeholders during market access, there are many different procedures and activities involved. The essential success characteristics that a business must implement in order to get easy market access are as follows:

How to choose the ideal KOLs for pharmaceutical marketing

Introduction Bringing your medications to market and establishing trust can be challenging processes. Healthcare professionals (HCPs) with substantial knowledge in particular therapeutic areas (TAs) of the pharmaceutical sector are known as key opinion leaders (KOLs) in the industry. Pharma companies need recommendations from professionals and word-of-mouth advertising. KOLs in the pharmaceutical industry are crucial in this situation. KOLs are primarily independent scientific and medical professionals who advise pharmaceutical firms on a variety of tasks, from pre-clinical and clinical stages of drug development research to clinical trials, regulatory approval, and product launch. KOL engagement helps pharmaceutical companies with new product development, data collection, strategy improvement, and creation of pertinent, reliable, and persuasive marketing messaging. KOLs in pharma: Benefits KOLs’ function in pharmaceutical market research Pharmaceutical companies look for KOLs with experience and expertise in their target therapeutic areas (TAs) to assist them with patient recruitment for clinical trials and data analysis. KOLs are crucial when it comes to spreading knowledge about new medications and treatments. In the medical community, they also give emerging treatments credence. A KOL can also instruct doctors on the physiological effects of a given medication and the types of patients who will benefit from it the most. Additionally, they can share information on treatment plans and describe their own firsthand knowledge of the therapies. Making a KOL engagement plan is therefore essential for brand acceptability in the pharmaceutical sector. The significance of KOL engagement KOL engagement, also known as KOL management, includes the full life cycle of selecting, evaluating, and working with the right KOLs in accordance with business objectives. It also includes planning research and marketing activities that involve them. KOL relationships should be based on trust and a shared desire for long-term cooperation. KOL engagement experiences an early rise, a plateau, and a gradual decline in involvement throughout the same lifecycle as the company’s products. Before recommending the best engagement strategy, pharma companies must ask pertinent questions to determine whether a particular KOL’s current work is in line with the company’s scientific and business goals. Choosing the best KOLs for your organization It is crucial to appropriately assess a KOL’s relative influence and TA proficiency. The following criteria can be used to assess a KOL’s strength based on their level of involvement, brand adoption, and influence behaviors: Learn how pharmaceutical companies utilized eMediWrite to partner with KOLs in their target TAs to create a panel of national experts across the country. Strong KOL management plans are essential for pharma companies in order to handle the shifting dynamics of KOLs in pharma.  An early KOL endorsement can generate a lot of attention in the industry and increase the efficacy of a breakthrough medication. But for pharmaceutical companies, finding, keeping, and managing KOLs has never been an easy task. Why and how eMediWrite can be useful Any KOL management procedure should be backed by thorough and reliable data sources. Additionally, the data is useless unless the right filters and analytics are applied to produce insightful results. As a result, businesses frequently turn to companies like eMediWrite. Global businesses can access full-service pharmaceutical market research services from eMediWrite in a variety of therapeutic areas. We combine local knowledge with deep insight from rigorously verified KOLs, including doctors, nurses, allied healthcare professionals, administrators, thought leaders, and payers. Contact us right away to learn more about how we can assist you.

Regulatory Compliance: Ensuring that pharmaceutical products meet all regulatory requirements and guidelines, including safety, efficacy, labelling, and post-marketing surveillance

From the examination of raw materials through the release of the finished packaged product, Quality Control Authorities like Central Drugs Standard Control Organisation in India established under the Drugs & Cosmetics Act, 1940. Central Drugs Standard Control Organisation (earlier known as Drugs Controller General of India) are essential to the pharmaceutical production process. They play a crucial role in assuring the efficacy and safety of products given to patients. The CDSCO headquarters conduct regulatory supervision over drug importation, approval of new pharmaceuticals and clinical trials, meetings of the Drugs Consultative Committee (DCC) and Drugs Technical Advisory Board (DTAB), and approval of some licences as the Central Licence Approving Authority. Laboratory Information Management Systems (LIMS), tailored to the needs of pharmaceutical manufacturing and quality assurance/quality control (QA/QC) laboratories, are proving to be a powerful force in enabling the industry to meet these challenges. Capable of integrating multiple functions and processes, these systems reduce reliance on off-line methods and manual transcription for managing, tracking and applying the large volume of data generated as part of manufacturing processes. As a result, laboratories can more easily identify cost reduction strategies, while meeting regulatory standards and ensuring the security of their data. Central Drugs Standard Control Organisation (QCA) provides one of the most crucial roles in pharmaceutical manufacture and supervision, according to the FDA. The quality control Authority and product testing are covered in great detail by the CGMP requirements. In order to manufacture pharmaceuticals products, the Central Drugs Standard Control Organisation is essential. The tests it does verify the quality of the products, and the reports it produces serve as the written proof. Tests conducted at different phases like Phase I, Phase II and Phase III of the production process create enormous volumes of data, which should show if quality has been maintained. Since any inaccuracies might lead to the production of goods that might be ineffective or endanger human safety, it is understandable that regulatory oversight of QC Authority data is rigorous. A company’s systems transparency may also be shown by such data.

Pharmaceutical product positioning

The process of giving a pharmaceutical product a unique identity on the market is called pharmaceutical product positioning. It entails recognising the special qualities and advantages of your product and conveying them to the intended market in a way that sets it apart from rival goods. Your pharmaceutical firm can gain a competitive edge, boost sales, and develop brand loyalty by using effective product positioning. Consider the following SIX actions when positioning your pharmaceutical product: A thorough awareness of the target market and the competitive environment is necessary for effective pharmaceutical product positioning. Pharmaceutical firms can distinguish their goods and increase market potential by creating a clear and attractive positioning plan.

How pharma knowledge and marketing influences prescriptions written by doctors

Knowledge marketing is a crucial method for influencing doctors’ prescription practises in the pharmaceutical business. Pharma marketers employ various knowledge marketing strategies and initiatives with the goal of influencing HCPs’ prescribing behaviour. These consist of: Pharmaceutical marketers typically don’t spend enough on patient education. However, HCPs increasingly favour pharmaceutical firms that place a greater emphasis on patient interaction and education. In various ways, patient education may be extremely influential in how doctors prescribe: By enhancing patient empowerment, lowering healthcare costs, and boosting adherence, patient education can significantly affect how doctors prescribe. Doctors may be more inclined to recommend medications and therapies that may effectively improve patient outcomes if patients are given educational information and tools.

Must know facts about Video marketing in Healthcare

Different types of video media are used in video marketing to advertise and market the goods and services offered by healthcare companies. An astounding 86% of healthcare companies use video marketing as a marketing strategy. Video has been shown to Although video marketing has been shown to be beneficial for all business kinds, it is especially well suited to the promotion of healthcare products since it can make complex information accessible to a large audience. Video production can be challenging; outsourcing it to a medical communications agency will simplify the process, allay any worries, and guarantee that your film is appealing, marketable, and matches your business’s goals.